$PIII

Hudson Vegas Investment SPV, LLC sold $824K of PIII

Hudson Vegas Investment SPV, LLC sold 50,000 shares of P3 Health Partners Inc. (PIII) at an average of $16.48 ($13.38–$16.86, $0.82M total) across 3 trades on 2026-08-10.

Original reporting
SEC EDGAR · Hudson Vegas Investment SPV, LLC
Published Aug 12, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PIII
Neutral
medium confidence
Mentioned
$PIII
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PIIINeutralLow
01

Why it matters

A large 10% owner sold shares in open-market trades totaling $823,927 and reported holdings after the transaction at 0 shares; no accompanying fundamental catalyst is provided.

02

Market read

Traders may monitor for additional insider activity, but the filing alone does not change the company’s fundamentals.

03

What to watch

No 10b5-1 plan is cited, but the filing does not state reasons for sale, and the transaction size may still be routine for a 10% owner.

Relevance 5/10Novelty 5/10Timing: Filed 2026-08-12, reporting sales executed 2026-08-10.

Background

The article is an SEC Form 4 insider transaction disclosure for P3 Health Partners Inc. (PIII).

Company-level read

Ticker impact

$PIIINeutralMedium confidence
Context

Hudson Vegas Investment SPV, LLC, a 10% owner of P3 Health Partners, sold about 50,000 shares in open-market trades totaling $823,927.

Expected impact

Near-term impact likely limited to sentiment, with follow-through depending on whether additional sales are disclosed.

Evidence & confidence

Form 4 shows the holder reduced to 0 shares after selling; however, the filing provides no new operating, guidance, or regulatory information, and insider sales are often non-informational.

Market effects

Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or reimbursement changes.

None indicated.

None indicated.

Counterpoint

The holder sold across a range of prices and ended with zero shares, which could reflect diversification or liquidity needs rather than negative expectations.

Key entities

  • P3 Health Partners Inc.

    Company whose shares were sold by a 10% owner, disclosed via SEC Form 4.

  • Hudson Vegas Investment SPV, LLC

    Reporting insider who executed the open-market sale and reduced holdings to zero.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PIIIMedAI 9/10

P3 Health Partners (PIII) Q2 2026 Earnings Call Transcript

P3 Health Partners (PIII) reported Q2 2026 adjusted EBITDA of $54.4 million versus a prior-year loss, on total revenue of $386.4 million (+9% YoY). At-risk membership fell 10% to 105,000. Net income was $15.7 million. The company raised full-year 2026 guidance to adjusted EBITDA of $80 million to $110 million and revenue of $1.5 billion to $1.6 billion.

$PIIIHigh

P3 Health Partners Inc. (PIII): Results of Operations and Financial Condition

P3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 P3 Health Partners Announces Second Quarter 2026 Results Raises Full-Year 2026 Adjusted EBITDA Guidance Management to Host Conference Call and Webcast August 10, 2026 at 4:30 PM ET HENDERSON, NV—August 10, 2026—P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ:

$PIIIMedAI 8/10

Short Interest in P3 Health Partners Inc. (NASDAQ:PIII) Rises By 293.3%

P3 Health Partners (NASDAQ:PIII) reported short interest of 283,541 shares as of May 15, up 293.3% from 72,094 on April 30; about 4.8% of shares are sold short, with a days-to-cover ratio near 0.0. The stock fell 26% on Friday to $12.18. UBS and Lake Street set $14 targets; TD Cowen reiterated hold. The company reported Q1 EPS of $0.32 on revenue of $386.39M.

$QTTBMedAI 9/10

Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX

Biotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).